These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 3910488)
1. The effect of insulin deprivation on fasting levels of 5000 dalton gastric inhibitory polypeptide in type 1 (insulin-dependent) diabetics. Krarup T; Madsbad S; Regeur L; Alberti KG; Faber OK; Kurtz A Diabete Metab; 1985 Dec; 11(6):364-7. PubMed ID: 3910488 [TBL] [Abstract][Full Text] [Related]
2. Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus. Jones IR; Owens DR; Luzio S; Hayes TM Horm Metab Res; 1989 Jan; 21(1):23-6. PubMed ID: 2647605 [TBL] [Abstract][Full Text] [Related]
3. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954 [TBL] [Abstract][Full Text] [Related]
4. Gastric inhibitory polypeptide in newly diagnosed ketotic type I (insulin-dependent) diabetics. Krarup T; Madsbad S; Moody AJ Acta Med Scand; 1988; 223(5):437-41. PubMed ID: 3287838 [TBL] [Abstract][Full Text] [Related]
5. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793 [TBL] [Abstract][Full Text] [Related]
6. The effect of somatostatin on fasting and postprandial plasma GIP, serum insulin, and blood glucose in man. Jorde R; Waldum HL; Burhol PG; Lygren I; Schulz TB; Florholmen J; Jenssen TG Scand J Gastroenterol; 1981; 16(1):113-9. PubMed ID: 6112787 [TBL] [Abstract][Full Text] [Related]
7. Effect of exogenous insulin on fasting serum levels of gastric inhibitory polypeptide (GIP) in juvenile diabetes. Talaulicar M; Ebert R; Willms B; Creutzfeldt W Clin Endocrinol (Oxf); 1981 Feb; 14(2):175-80. PubMed ID: 7021006 [TBL] [Abstract][Full Text] [Related]
8. Different response of gastric inhibitory polypeptide to glucose and fat from duodenum and jejunum. Schattenmann G; Ebert R; Siewert R; Creutzfeldt W Scand J Gastroenterol; 1984 Mar; 19(2):260-6. PubMed ID: 6372074 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of immunoreactive gastric inhibitory polypeptide in the plasma of newly diagnosed type 1 (insulin-dependent) diabetics. Krarup T; Holst JJ; Madsbad S Acta Endocrinol (Copenh); 1987 Jan; 114(1):74-83. PubMed ID: 3544634 [TBL] [Abstract][Full Text] [Related]
10. Immunoreactive gastric inhibitory polypeptide response to a meal during the first eighteen months after diagnosis of type 1 (insulin dependent) diabetes mellitus. Krarup T; Madsbad S; Moody AJ J Clin Endocrinol Metab; 1985 Jan; 60(1):120-5. PubMed ID: 3880559 [TBL] [Abstract][Full Text] [Related]
11. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Vilsbøll T; Krarup T; Madsbad S; Holst JJ Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441 [TBL] [Abstract][Full Text] [Related]
12. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091 [TBL] [Abstract][Full Text] [Related]
14. Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. Krarup T; Saurbrey N; Moody AJ; Kühl C; Madsbad S Metabolism; 1987 Jul; 36(7):677-82. PubMed ID: 3298936 [TBL] [Abstract][Full Text] [Related]
15. Effect of graded intraduodenal glucose infusions on the release and physiological action of gastric inhibitory polypeptide. McCullough AJ; Miller LJ; Service FJ; Go VL J Clin Endocrinol Metab; 1983 Feb; 56(2):234-41. PubMed ID: 6337173 [TBL] [Abstract][Full Text] [Related]
16. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937 [TBL] [Abstract][Full Text] [Related]
17. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. Irwin N; McClean PL; Patterson S; Hunter K; Flatt PR Biol Chem; 2009 Jan; 390(1):75-80. PubMed ID: 18937625 [TBL] [Abstract][Full Text] [Related]
19. Relation of immunoreactive gastric inhibitory polypeptide to changes in glycaemic control and B cell function in type 1 (insulin-dependent) diabetes mellitus. Krarup T; Madsbad S; Regeur L; Faber OK; Tronier B Acta Endocrinol (Copenh); 1984 Feb; 105(2):221-5. PubMed ID: 6364671 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of gastric inhibitory polypeptide (GIP) release by insulin and glucose in juvenile diabetes. Creutzfeldt W; Talaulicar M; Ebert R; Willms B Diabetes; 1980 Feb; 29(2):140-5. PubMed ID: 6986299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]